AmplifyBio

AmplifyBio, founded in 2021 as a spinoff from Battelle Memorial Institute, was a contract research and development organization serving cell and gene therapy companies. The firm offered a broad suite of services including preclinical safety and toxicology testing, discovery research such as T-cell and CAR-T development, and advanced therapy manufacturing capabilities spanning plasmid, mRNA, and cell therapies.

Hilco Streambank was engaged, alongside Hilco Real Estate and Hilco Commercial Industrial, to monetize AmplifyBio’s assets as part of its Chapter 11 proceedings. Hilco Streambank led the marketing and sale of AmplifyBio’s patent portfolio, which covers technologies in TCR therapeutics, gene editing, T cell manipulation, and molecular interactions.

Hilco helped secure Battelle as the stalking-horse bidder for all assets early in the process. Through comprehensive outreach, the Hilco teams generated competitive interest and additional bids for the intellectual property and equipment. The process culminated in an auction conducted by lot. Battelle was the successful bidder across all lots and acquired all assets.

This engagement highlights Hilco’s ability to coordinate across practice groups to maximize value in distressed situations.